About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Nanobiotix announces key development milestones for 2021 after successful Nasdaq initial public offering
Nanobiotix announces closing of underwriters’ option to purchase additional ADSs
18 December 2020
Nanobiotix announces positive first results for novel NBTXR3 in rectal cancer study at ASCO-GI 2021
15 January 2021
Nanobiotix announces key development milestones for 2021 after successful Nasdaq initial public offering
Published by
Julie Ficheux
on
8 January 2021
